• Read more about Section 60, Medical Supplies and Durable Medical Equipment (DME): Summary of Rate Forum Comments and Department Responses

In September of 2022, the Office of MaineCare Services provided public notice that it initiated a rate determination for Section 60 Medical Supplies and DME prior to P.L. 2021 Ch. 639.

• Read more about Maine DHHS Temporarily Closes Lewiston Office Due to Damage From Cold Weather

AUGUSTA — The Maine Department of Health and Human Services (DHHS) closed its district office at 200 Main Street in Lewiston today due to water and electrical damage resulting from the extreme cold weather in the past few days. The office is undergoing repairs and will reopen to the public and employees as soon as possible to ensure continued access to critical benefits and services.

• Read more about Attention Providers of Sections 17, 28, and 65: Behavioral Health Rate FAQs

As mentioned in the notice on February 2, 2023, the Department now has available the Behavioral Health Rate FAQ document on billing and authorizations for serv

• Read more about Attention Providers of Section 31 Federally Qualified Health Centers (FQHC): Rebasing Stakeholder Informational Session: Presented Materials

As previously shared in our September 27, 2022 bulletin, the Department initiated a rate determination process for Section 31, Federally Qualified Health Centers, (FQHCs).   

• Read more about Limited Availability of MaineCare Preferred Albuterol Products

Effective January 20, 2023, MaineCare added additional albuterol products with preferred status to our Preferred Drug List (PDL). These preferred products do not require prior authorization (PA): 

• Read more about XDEA License Requirement for Buprenorphine Claims Removed

On December 29, 2022, Congress eliminated the “DATA-Waiver Program” with the signing of the Consolidated Appropriations Act of 2023 (the Act), improving access to buprenorphine for those in need.    

• Read more about XDEA License Requirement for Buprenorphine Claims Removed

On December 29, 2022, Congress eliminated the “DATA-Waiver Program” with the signing of the Consolidated Appropriations Act of 2023 (the Act), improving access to buprenorphine for those in need.    

• Read more about XDEA License Requirement for Buprenorphine Claims Removed

On December 29, 2022, Congress eliminated the “DATA-Waiver Program” with the signing of the Consolidated Appropriations Act of 2023 (the Act), improving access to buprenorphine for those in need.    

• Read more about XDEA License Requirement for Buprenorphine Claims Removed

On December 29, 2022, Congress eliminated the “DATA-Waiver Program” with the signing of the Consolidated Appropriations Act of 2023 (the Act), improving access to buprenorphine for those in need.